Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Influenza A Virus, H3N2 Subtype | 10 | 2019 | 572 | 1.08 | Why? |
| Microcystis | 3 | 2017 | 16 | 1.06 | Why? |
| Iron | 7 | 2019 | 619 | 1.00 | Why? |
| Ferric Compounds | 4 | 2019 | 136 | 1.00 | Why? |
| Influenza B virus | 9 | 2019 | 815 | 0.94 | Why? |
| Gene Expression Regulation, Leukemic | 1 | 2018 | 31 | 0.77 | Why? |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 31 | 0.74 | Why? |
| Fresh Water | 1 | 2018 | 59 | 0.73 | Why? |
| Influenza, Human | 22 | 2021 | 10779 | 0.71 | Why? |
| Influenza A Virus, H1N1 Subtype | 12 | 2019 | 2984 | 0.61 | Why? |
| Influenza A Virus, H1N2 Subtype | 4 | 2017 | 19 | 0.58 | Why? |
| Population Surveillance | 11 | 2019 | 4967 | 0.55 | Why? |
| Oxidation-Reduction | 9 | 2019 | 540 | 0.55 | Why? |
| Rivers | 5 | 2019 | 304 | 0.42 | Why? |
| Biomarkers, Tumor | 1 | 2018 | 1314 | 0.39 | Why? |
| Influenza A Virus, H7N2 Subtype | 2 | 2017 | 11 | 0.35 | Why? |
| Reactive Oxygen Species | 2 | 2017 | 1136 | 0.33 | Why? |
| Benzoquinones | 1 | 2007 | 92 | 0.32 | Why? |
| Hospitalization | 23 | 2021 | 54280 | 0.32 | Why? |
| Silver | 2 | 2019 | 327 | 0.30 | Why? |
| Child Mortality | 7 | 2019 | 163 | 0.27 | Why? |
| Metal Nanoparticles | 2 | 2019 | 771 | 0.22 | Why? |
| Drug Resistance, Viral | 8 | 2019 | 1083 | 0.22 | Why? |
| Seasons | 12 | 2019 | 4071 | 0.22 | Why? |
| United States | 26 | 2021 | 46150 | 0.22 | Why? |
| Hydrogen-Ion Concentration | 3 | 2019 | 993 | 0.21 | Why? |
| Superoxides | 1 | 2019 | 36 | 0.21 | Why? |
| Groundwater | 1 | 2019 | 45 | 0.19 | Why? |
| Biological Availability | 2 | 2017 | 388 | 0.19 | Why? |
| Influenza Vaccines | 7 | 2019 | 2941 | 0.19 | Why? |
| Arsenic | 1 | 2019 | 85 | 0.19 | Why? |
| Phosphorus Compounds | 1 | 2017 | 2 | 0.18 | Why? |
| Magnesium Oxide | 1 | 2017 | 3 | 0.18 | Why? |
| Strontium | 1 | 2017 | 3 | 0.18 | Why? |
| Ferrous Compounds | 1 | 2017 | 23 | 0.17 | Why? |
| Calcium Compounds | 1 | 2017 | 13 | 0.17 | Why? |
| Microalgae | 1 | 2017 | 38 | 0.17 | Why? |
| Adolescent | 23 | 2021 | 86841 | 0.17 | Why? |
| Glass | 1 | 2017 | 78 | 0.17 | Why? |
| Vasoconstrictor Agents | 1 | 2021 | 714 | 0.17 | Why? |
| Oxides | 1 | 2017 | 77 | 0.16 | Why? |
| Silicon Dioxide | 1 | 2017 | 131 | 0.16 | Why? |
| Pregnancy Outcome | 2 | 2020 | 3803 | 0.15 | Why? |
| Infant Mortality | 4 | 2019 | 268 | 0.15 | Why? |
| Water Purification | 1 | 2019 | 285 | 0.15 | Why? |
| Text Messaging | 1 | 2020 | 389 | 0.15 | Why? |
| Infant | 13 | 2020 | 30274 | 0.14 | Why? |
| Parturition | 1 | 2019 | 514 | 0.14 | Why? |
| Copper | 1 | 2018 | 288 | 0.14 | Why? |
| Epidemiologic Methods | 1 | 2018 | 392 | 0.14 | Why? |
| Child, Preschool | 13 | 2020 | 36283 | 0.13 | Why? |
| Laboratories | 3 | 2021 | 2858 | 0.13 | Why? |
| Water Pollutants, Chemical | 1 | 2019 | 410 | 0.13 | Why? |
| Conjunctivitis, Viral | 1 | 2018 | 301 | 0.13 | Why? |
| Hydrogen Peroxide | 3 | 2019 | 680 | 0.12 | Why? |
| Sentinel Surveillance | 1 | 2020 | 1093 | 0.12 | Why? |
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 1316 | 0.12 | Why? |
| Oseltamivir | 1 | 2016 | 583 | 0.12 | Why? |
| Calcium | 1 | 2017 | 708 | 0.12 | Why? |
| Young Adult | 18 | 2021 | 93724 | 0.12 | Why? |
| Age Distribution | 1 | 2021 | 3567 | 0.11 | Why? |
| Infant, Newborn | 11 | 2020 | 23105 | 0.11 | Why? |
| Outpatients | 6 | 2019 | 3417 | 0.11 | Why? |
| Child | 15 | 2021 | 70012 | 0.11 | Why? |
| Adult | 24 | 2021 | 244371 | 0.10 | Why? |
| Influenza A virus | 2 | 2019 | 2234 | 0.10 | Why? |
| Homeless Persons | 1 | 2021 | 1171 | 0.10 | Why? |
| Respiratory Tract Infections | 2 | 2021 | 6817 | 0.10 | Why? |
| Middle Aged | 22 | 2021 | 270681 | 0.09 | Why? |
| Photochemistry | 1 | 2007 | 13 | 0.09 | Why? |
| Pneumonia | 8 | 2019 | 5652 | 0.09 | Why? |
| Solutions | 1 | 2007 | 121 | 0.08 | Why? |
| Premature Birth | 1 | 2018 | 2151 | 0.08 | Why? |
| Immunity, Cellular | 1 | 2019 | 3614 | 0.08 | Why? |
| Length of Stay | 2 | 2021 | 11042 | 0.07 | Why? |
| Humans | 35 | 2021 | 930598 | 0.07 | Why? |
| Thailand | 2 | 2019 | 1155 | 0.07 | Why? |
| Male | 17 | 2021 | 367725 | 0.07 | Why? |
| Adrenal Cortex Hormones | 1 | 2021 | 6537 | 0.07 | Why? |
| Aged | 15 | 2021 | 215776 | 0.07 | Why? |
| Adenosine Monophosphate | 1 | 2021 | 5652 | 0.07 | Why? |
| Alanine | 1 | 2021 | 5687 | 0.07 | Why? |
| Female | 17 | 2021 | 380317 | 0.06 | Why? |
| Pregnancy Complications, Infectious | 2 | 2020 | 11559 | 0.06 | Why? |
| HIV Infections | 2 | 2019 | 11620 | 0.06 | Why? |
| Communicable Diseases | 1 | 2018 | 2148 | 0.06 | Why? |
| Severity of Illness Index | 6 | 2021 | 48226 | 0.06 | Why? |
| Behavioral Risk Factor Surveillance System | 1 | 2021 | 66 | 0.06 | Why? |
| Antiviral Agents | 6 | 2021 | 41703 | 0.06 | Why? |
| Vaccination | 4 | 2020 | 19050 | 0.05 | Why? |
| Cohort Effect | 1 | 2019 | 12 | 0.05 | Why? |
| Intensive Care Units | 3 | 2021 | 29594 | 0.05 | Why? |
| Benzopyrans | 1 | 2019 | 39 | 0.05 | Why? |
| Hemagglutination Inhibition Tests | 1 | 2019 | 191 | 0.05 | Why? |
| Kinetics | 2 | 2018 | 3238 | 0.05 | Why? |
| Oxidants | 1 | 2018 | 72 | 0.05 | Why? |
| Health Personnel | 2 | 2020 | 29646 | 0.05 | Why? |
| Adsorption | 1 | 2019 | 261 | 0.05 | Why? |
| Buffers | 1 | 2018 | 82 | 0.05 | Why? |
| Phase Transition | 1 | 2017 | 25 | 0.04 | Why? |
| Ceramics | 1 | 2017 | 26 | 0.04 | Why? |
| Malawi | 1 | 2018 | 287 | 0.04 | Why? |
| Utah | 1 | 2019 | 425 | 0.04 | Why? |
| Organic Chemicals | 1 | 2018 | 90 | 0.04 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.04 | Why? |
| Interleukin-2 | 1 | 2019 | 443 | 0.04 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.04 | Why? |
| Minnesota | 1 | 2019 | 509 | 0.04 | Why? |
| Pandemics | 10 | 2021 | 389249 | 0.04 | Why? |
| Missouri | 1 | 2017 | 274 | 0.04 | Why? |
| Long-Term Care | 2 | 2020 | 2047 | 0.04 | Why? |
| United States Department of Veterans Affairs | 1 | 2020 | 553 | 0.04 | Why? |
| X-Ray Diffraction | 1 | 2017 | 249 | 0.04 | Why? |
| Ambulatory Care | 3 | 2018 | 4947 | 0.04 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.04 | Why? |
| Pregnancy | 4 | 2020 | 23879 | 0.04 | Why? |
| Laboratories, Hospital | 1 | 2020 | 489 | 0.04 | Why? |
| Tissue Scaffolds | 1 | 2017 | 174 | 0.04 | Why? |
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2019 | 511 | 0.04 | Why? |
| Residential Facilities | 1 | 2020 | 443 | 0.04 | Why? |
| Light | 1 | 2017 | 306 | 0.04 | Why? |
| Biocompatible Materials | 1 | 2017 | 214 | 0.04 | Why? |
| Pediatric Obesity | 1 | 2020 | 492 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 8811 | 0.03 | Why? |
| Materials Testing | 1 | 2017 | 380 | 0.03 | Why? |
| CD4 Lymphocyte Count | 1 | 2019 | 1517 | 0.03 | Why? |
| Peru | 1 | 2018 | 1010 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2021 | 53120 | 0.03 | Why? |
| Oxygen | 1 | 2007 | 3715 | 0.03 | Why? |
| Clinical Laboratory Services | 1 | 2020 | 781 | 0.03 | Why? |
| Incidence | 3 | 2021 | 25622 | 0.03 | Why? |
| Respiratory Tract Diseases | 1 | 2020 | 1061 | 0.03 | Why? |
| Water | 1 | 2017 | 765 | 0.03 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.03 | Why? |
| Longitudinal Studies | 2 | 2018 | 9893 | 0.03 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.03 | Why? |
| Cell Survival | 1 | 2017 | 1581 | 0.03 | Why? |
| Risk Factors | 4 | 2021 | 71621 | 0.03 | Why? |
| Feasibility Studies | 1 | 2020 | 3467 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2017 | 27595 | 0.02 | Why? |
| Interferon-gamma | 1 | 2019 | 2711 | 0.02 | Why? |
| Prospective Studies | 3 | 2020 | 43301 | 0.02 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2019 | 2483 | 0.02 | Why? |
| Propensity Score | 1 | 2017 | 2690 | 0.02 | Why? |
| Infection Control | 1 | 2017 | 23131 | 0.02 | Why? |
| Pilot Projects | 1 | 2020 | 5182 | 0.02 | Why? |
| Cost of Illness | 1 | 2019 | 1903 | 0.02 | Why? |
| Cell Line, Tumor | 1 | 2017 | 3608 | 0.02 | Why? |
| Asymptomatic Diseases | 1 | 2020 | 3444 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2019 | 3567 | 0.02 | Why? |
| Waste Water | 1 | 2018 | 2185 | 0.02 | Why? |
| Acute Disease | 1 | 2020 | 6029 | 0.02 | Why? |
| Risk | 1 | 2019 | 5288 | 0.02 | Why? |
| Oxidative Stress | 1 | 2018 | 2050 | 0.02 | Why? |
| Hospital Mortality | 2 | 2021 | 22087 | 0.02 | Why? |
| Odds Ratio | 1 | 2018 | 5861 | 0.02 | Why? |
| New York City | 1 | 2020 | 7432 | 0.02 | Why? |
| Poverty | 1 | 2018 | 2302 | 0.02 | Why? |
| Antibody Formation | 1 | 2019 | 4038 | 0.02 | Why? |
| Chronic Disease | 1 | 2020 | 5139 | 0.02 | Why? |
| B-Lymphocytes | 1 | 2019 | 4418 | 0.02 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2019 | 4545 | 0.02 | Why? |
| Immunocompromised Host | 1 | 2020 | 5150 | 0.02 | Why? |
| Health Status Disparities | 1 | 2020 | 4072 | 0.02 | Why? |
| Mortality | 1 | 2019 | 7132 | 0.01 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2019 | 5837 | 0.01 | Why? |
| India | 1 | 2018 | 11875 | 0.01 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.01 | Why? |
| Coinfection | 1 | 2017 | 6820 | 0.01 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.01 | Why? |
| Prevalence | 1 | 2019 | 25773 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Retrospective Studies | 2 | 2017 | 105322 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2019 | 21571 | 0.01 | Why? |
| Treatment Outcome | 1 | 2021 | 51732 | 0.01 | Why? |
| Cohort Studies | 1 | 2016 | 36005 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.01 | Why? |
| Antibodies, Viral | 1 | 2019 | 51949 | 0.00 | Why? |
Garg's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(178)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(176)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_